Skip to main content
. 2023 Mar 4;128(10):1897–1905. doi: 10.1038/s41416-023-02212-2

Fig. 4. Adjusted overall survival curves.

Fig. 4

a intent-to-use 5-FU, b intent-to-use S-1, c baseline sum of the diameter of target lesions ≥60 mm, and d baseline sum of the diameter of target lesions <60 mm. 5-FU 5-fluorouracil, BEV bevacizumab, CI confidence interval, FOLFIRI 5-FU, leucovorin, and irinotecan, FP fluoropyrimidine, FTD/TPI trifluridine/tipiracil, HR hazard ratio, IRI irinotecan, NE not estimable. aAdjusted based on stratification factors.